Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ymthe.2021.04.022 http://scihub22266oqcxt.onion/10.1016/j.ymthe.2021.04.022 33895322!8062434!33895322     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Mol+Ther 2021 ; 29 (8): 2412-2423 Nephropedia Template TP {{tp|p=33895322|t=2021. Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19 |pdf=|usr=}}{{33895322}} gab.com Text Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19 JO: Mol Ther http://www.kidney.de/pget.php?&tw=1&pmid=33895322 #FOAvip The coronavirus disease 2019 (COVID-19) pandemic caused by the emergent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health, and there is an urgent need to develop safe and effective vaccines. Here, we report the generation and the preclinical evaluation of a novel replication-defective gorilla adenovirus-vectored vaccine encoding the pre-fusion stabilized Spike (S) protein of SARS-CoV-2. We show that our vaccine candidate, GRAd-COV2, is highly immunogenic both in mice and macaques, eliciting both functional antibodies that neutralize SARS-CoV-2 infection and block Spike protein binding to the ACE2 receptor, and a robust, T helper (Th)1-dominated cellular response. We show here that the pre-fusion stabilized Spike antigen is superior to the wild type in inducing ACE2-interfering, SARS-CoV-2-neutralizing antibodies. To face the unprecedented need for vaccine manufacturing at a massive scale, different GRAd genome deletions were compared to select the vector backbone showing the highest productivity in stirred tank bioreactors. This preliminary dataset identified GRAd-COV2 as a potential COVID-19 vaccine candidate, supporting the translation of the GRAd-COV2 vaccine in a currently ongoing phase I clinical trial (ClinicalTrials.gov: NCT04528641). Twit Text FOAVip Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19 ????Mol Ther http://www.kidney.de/pget.php?&tw=1&pmid=33895322 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33895322 #FOAvip English Wikipedia <ref>{{Cite pmid|33895322}}</ref> Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19 #MMPMID33895322 Capone S; Raggioli A; Gentile M; Battella S; Lahm A; Sommella A; Contino AM; Urbanowicz RA; Scala R; Barra F; Leuzzi A; Lilli E; Miselli G; Noto A; Ferraiuolo M; Talotta F; Tsoleridis T; Castilletti C; Matusali G; Colavita F; Lapa D; Meschi S; Capobianchi M; Soriani M; Folgori A; Ball JK; Colloca S; Vitelli A Mol Ther 2021[Aug]; 29 (8): 2412-2423 PMID33895322show ga The coronavirus disease 2019 (COVID-19) pandemic caused by the emergent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health, and there is an urgent need to develop safe and effective vaccines. Here, we report the generation and the preclinical evaluation of a novel replication-defective gorilla adenovirus-vectored vaccine encoding the pre-fusion stabilized Spike (S) protein of SARS-CoV-2. We show that our vaccine candidate, GRAd-COV2, is highly immunogenic both in mice and macaques, eliciting both functional antibodies that neutralize SARS-CoV-2 infection and block Spike protein binding to the ACE2 receptor, and a robust, T helper (Th)1-dominated cellular response. We show here that the pre-fusion stabilized Spike antigen is superior to the wild type in inducing ACE2-interfering, SARS-CoV-2-neutralizing antibodies. To face the unprecedented need for vaccine manufacturing at a massive scale, different GRAd genome deletions were compared to select the vector backbone showing the highest productivity in stirred tank bioreactors. This preliminary dataset identified GRAd-COV2 as a potential COVID-19 vaccine candidate, supporting the translation of the GRAd-COV2 vaccine in a currently ongoing phase I clinical trial (ClinicalTrials.gov: NCT04528641). |Adenoviridae/*immunology[MESH] |Adenovirus Vaccines/*immunology[MESH] |Adolescent[MESH] |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Animals[MESH] |Antibodies, Neutralizing/immunology[MESH] |Antibodies, Viral/immunology[MESH] |COVID-19 Vaccines/*immunology[MESH] |COVID-19/*immunology[MESH] |Cell Line[MESH] |Cell Line, Tumor[MESH] |Female[MESH] |Genetic Vectors/immunology[MESH] |Gorilla gorilla/*immunology/virology[MESH] |HEK293 Cells[MESH] |HeLa Cells[MESH] |Humans[MESH] |Immunogenicity, Vaccine/*immunology[MESH] |Macaca[MESH] |Male[MESH] |Mice[MESH] |Mice, Inbred BALB C[MESH] |Middle Aged[MESH] |Pandemics/prevention & control[MESH] |SARS-CoV-2/*immunology[MESH]Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID(epmc).pdf DeepDyve Pubget Overpricing